

Genetic testing of the *AR* Gene for Spinal and Bulbar Muscular Atrophy

Disorder also known as: Kennedy Disease; KD; SBMA; X-linked Spinal and Bulbar Muscular Atrophy; SMAX1; Bulbosplinal Neuronopathy, X-linked Recessive; XBSN

Clinical Features:

Spinal and bulbar muscular atrophy (SBMA) is a slowly progressive neuromuscular disorder in which degeneration of the lower motor neurons causes muscle weakness, muscle atrophy, and fasciculations of the perioral region. The onset of disease ranges from 18-64 years of age, with most individuals presenting in the fourth or fifth decade.¹ Androgen insensitivity, resulting in gynecomastia, testicular atrophy, and oligospermia/azoospermia, can present in adolescence.² The onset of neurological symptoms typically ranges from 30-50 years of age; features can include muscle cramps, active tremor, decreased deep tendon reflexes, difficulty walking, and frequent falls due to muscle weakness.² As the proximal and distal weakness and atrophy progresses, ambulation becomes more difficult. Bulbar muscle involvement typically progresses early in the fifth decade resulting in difficulties in articulation (dysarthria) and difficulty swallowing (dysphagia).³ In a minority of individuals with SBMA there is a risk for potentially life-threatening aspiration pneumonia and respiratory failure as a result of weakness in the bulbar and respiratory musculature.^{3,4} Histopathology findings include degeneration of motor neurons in the spinal cord and brainstem, and the identification of nuclear inclusions containing abnormal androgen receptor protein in the remaining motor neurons.^{5, 6, 7} Electromyography (EMG) findings include anterior horn cell loss, sensory neuropathy, and diffuse denervation atrophy.⁸ The prevalence of SBMA is estimated at 1:40,000-1:50,000 males, with a higher prevalence in European and Asian populations.^{2, 7}

Genetics:

SBMA is inherited in an X-linked manner. It is caused by expansion of the glutamine repeat (CAG) in exon 1 of the androgen receptor (*AR*) gene.² Normal alleles have between 11 and 34 CAG trinucleotide repeats, and disease alleles have greater than 38 repeats.^{1,3} Reduced penetrance has been observed in families with alleles that have 35-37 repeats. In those individuals that have alleles within the reduced penetrance range, clinical significance should be interpreted within the context of the individual's clinical presentation and family history.² There is an inverse correlation between CAG repeat length and age of onset, as well as a direct correlation between repeat length and disease severity.^{3,9} The glutamine repeat in *AR* is meiotically unstable, leading to expansion of the repeat during transmission from parent to offspring. While a correlation exists between repeat number and disease onset and severity, prediction of disease course cannot be based solely on the repeat number.¹⁰

Test Methods:

Using genomic DNA, CAG repeat analysis is performed using two complementary PCR assays. Each sample is evaluated by repeat primed PCR to identify an expanded allele, and standard PCR fragment analysis is used to determine the number of repeats in each allele. The combination of repeat primed PCR and fragment analysis allows for the definitive identification of an expanded allele, making it suitable for the evaluation of carrier status. The largest recorded allele of 78 repeats can be analyzed accurately using this strategy.

Test Sensitivity:

The clinical sensitivity for analysis of the glutamine repeat in AR depends on the clinical phenotype of the patient. All individuals with SBMA have an expansion of the glutamine repeat in exon 1 of the *AR* gene, which is detectable by this targeted mutation analysis⁸. The technical sensitivity of fragment analysis is estimated to be greater than 95%. Pathogenic single nucleotide variants and whole or partial deletions and duplications of the AR gene are not reported in association with SBMA and would not be detected by this analysis.

References:

1. Rhodes et al. (2009). Clinical features of spinal and bulbar muscular atrophy. *Brain* 157:290-294.
2. La Spada. (1999; Updated July 2014) Spinal and Bulbar Muscular Atrophy. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2014. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK1333/>
3. Atsuta et al. (2006). Natural history of spinal and bulbar muscular atrophy (SBMA): a study of 223 Japanese patients. *Brain* 129:1446-1455.
4. Kennedy et al. (1968) Progressive proximal spinal and bulbar muscular atrophy of later onset: A sex –linked recessive trait. *Neurology* 18:671-680
5. Adachi et al. (2005) Widespread nuclear and cytoplasmic accumulation of mutant androgen receptor in SBMA patients. *Brain* 128:659-70.
6. Li et al. (1998) Nuclear inclusions of the androgen receptor protein in spinal and bulbar muscular atrophy 44: 249-254.
7. Soraru et al. (2008) Spinal and bulbar muscular atrophy: skeletal muscle pathology in male patients and heterozygous females. *J Neurol Sci* 264: 100-105.
8. Olney et al., (1991) Clinical and electrodiagnostic features of X-linked recessive bulbospinal neuronopathy. *Neuro* 41: 823-8.
9. Doyu et al. (1992). Severity of X-linked recessive bulbospinal neuronopathy correlates with size of tandem CAG repeat in androgen receptor gene. *Ann Neurol* 32:707-710.
10. La Spada et al. (2010) Repeat expansion disease: progress and puzzles in disease pathogenesis. *Nat Rev Genet* 11:247-58.